Physiologist, keen electrophysiologist, passionate with intracellular signalling, cellular imaging and inter cell communcation, Eric obtained a MSc Degree in Physiology and Cellular Biology from the University of Sciences and Techniques of Tours (France). During his PhD, he worked on circulatory dysregulation and pulmonary hypertension triggered by respiratory diseases such as Chronic Obstructive Pulmonary Diseases (COPD) and athmospheric pollutants in animal models. Since completing his PhD, he successfully worked in the Physiology and Critical Care Research Departments of the University of Liverpool investigating cardiac and arterial disfunctions in models of cardiomyopathy and the impact of new antiarrythmic drugs on cardiomyocytes function. Following this, Eric joined the Respiratory Pharmacology Group at the Imperial College to give his contribution to the research of new treatment for common (asthma, COPD, ILF) and rare (RCC, UCC) respiratory diseases participating in the development of the new drug Lyfnua. Eric has now joined Astra Zeneca as an Associate Principal Scientist to further help the patients and participate in developping new treatments. Eric has a substantial publication record in peer review journals and is a recognised international expert in the respiratory and cardiovascular field.